Korsana Biosciences

📍 Waltham, United States👥 17 employees💰 Last funded Sep 2025
Biotechnology Research🌐 korsana.com
Website LinkedIn
Korsana Biosciences is a private biopharmaceutical company advancing a pipeline of potential best-in-class therapies for neurodegenerative diseases. In partnership with Paragon Therapeutics, we have developed Therapeutic Targeting (THETA™), a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Our lead program is KRSA-028, an investigational, shuttled antibody targeting amyloid beta designed to be a best-in-class treatment for Alzheimer’s disease. Our mission is to advance precision-engineered therapies, designed to address some of the biggest unmet needs in medicine. For more information, please visit www.korsana.com
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Korsana Biosciences?
Korsana Biosciences has 1 investors on record on gritt.io.
When did Korsana Biosciences last raise funding?
The most recent investment in Korsana Biosciences recorded on gritt.io was in September 2025.
What industry is Korsana Biosciences in?
Korsana Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Korsana Biosciences based?
Korsana Biosciences is headquartered in Waltham, United States.